EMD Serono Gets FDA Nod for Once-Daily Oral Therapy for Rare Joint Tumor

The FDA has approved EMD Serono’s Pimjetmi (pimicotinib), a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical removal could cause worsening functional limitations or severe morbidity.

Pimicotinib is a selective small-molecule inhibitor of colony-stimulating factor-1 receptor (CSF-1R), which plays a role in the growth and survival of cells involved in TGCT. The recommended dosage is 50 mg once daily, with or without food. 

The approval is supported by results from the phase 3 MANEUVER trial, which evaluated pimicotinib against placebo in 94 patients. At week 25, the objective response rate was 56% among patients receiving pimicotinib, compared with 3% for placebo. Treatment also produced statistically significant improvements in joint mobility, physical function and pain.

In longer-term follow-up, 77% of patients who responded to treatment at week 25 maintained their response after an additional 12 months. The most common adverse reactions included itching, rash, facial and peripheral swelling, fatigue, nausea and headache.

Pimjetmi carries warnings for hepatotoxicity and embryo-fetal toxicity. Patients require liver-function testing before treatment, monthly for the first three months, and every three months for the remainder of the first year.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox! Sign up now!